KAS
CRSP icon

Kestra Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History

Kestra Advisory Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1M Buy
21,052
+416
+2% +$21.9K ﹤0.01% 1733
2025
Q4 		$1.08M Buy
20,636
+1,528
+8% +$91.5K ﹤0.01% 1602
2025
Q3 		$1.24M Buy
19,108
+4,556
+31% +$262K 0.01% 1447
2025
Q2 		$708K Sell
14,552
-1,888
-11% -$73.1K ﹤0.01% 1722
2025
Q1 		$559K Buy
16,440
+432
+3% +$18.3K ﹤0.01% 1753
2024
Q4 		$630K Buy
16,008
+3,843
+32% +$181K ﹤0.01% 1712
2024
Q3 		$572K Sell
12,165
-3,949
-25% -$200K ﹤0.01% 1687
2024
Q2 		$870K Buy
16,114
+407
+3% +$23.5K ﹤0.01% 1407
2024
Q1 		$1.07M Buy
15,707
+4,310
+38% +$309K 0.01% 1192
2023
Q4 		$713K Buy
11,397
+5,769
+103% +$319K 0.01% 1310
2023
Q3 		$255K Sell
5,628
-469
-8% -$24.2K ﹤0.01% 1777
2023
Q2 		$342K Buy
6,097
+92
+2% +$5.22K ﹤0.01% 1529
2023
Q1 		$272K Sell
6,005
-276
-4% -$13.4K ﹤0.01% 1634
2022
Q4 		$255K Sell
6,281
-457
-7% -$24.2K ﹤0.01% 1856
2022
Q3 		$440K Sell
6,738
-99
-1% -$7.17K ﹤0.01% 1390
2022
Q2 		$415K Buy
6,837
+1,427
+26% +$83.9K ﹤0.01% 1430
2022
Q1 		$340K Buy
5,410
+1,102
+26% +$69.2K ﹤0.01% 1520
2021
Q4 		$326K Sell
4,308
-8,164
-65% -$713K ﹤0.01% 1561
2021
Q3 		$1.4M Buy
12,472
+272
+2% +$34.2K 0.01% 847
2021
Q2 		$1.98M Buy
12,200
+6,219
+104% +$756K 0.02% 659
2021
Q1 		$729K Sell
5,981
-4,756
-44% -$718K 0.01% 1008
2020
Q4 		$1.74M Buy
+10,737
New +$1.27M 0.02% 641

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kestra Advisory Services's CRSP Position: Q1 2026 in Review

Kestra Advisory Services increased its CRISPR Therapeutics (CRSP) stake by 2% in Q1 2026, buying an estimated $21.9K and bringing the position to 21,052 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #1733.

Kestra Advisory Services first reported a position in CRSP in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.98M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Kestra Advisory Services held 21,052 shares of CRISPR Therapeutics worth $1M as of Q1 2026.
  • Kestra Advisory Services bought 416 CRISPR Therapeutics shares in Q1 2026, an estimated $21.9K.
  • CRISPR Therapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q1 2026, its #1733 holding.
  • Kestra Advisory Services first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Kestra Advisory Services's CRISPR Therapeutics position peaked at $1.98M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.